The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy - PubMed
Review
The effect of estrogen on the sexual interest of castrated males: Implications to prostate cancer patients on androgen-deprivation therapy
Erik Wibowo et al. Crit Rev Oncol Hematol. 2013 Sep.
Abstract
Androgen deprivation therapy (ADT) for prostate cancer (PCa) treatment causes sexual dysfunction. We review here the effects of estrogen on the sexual performance of androgen-deprived males. The major findings are: 1. Estrogen receptors are present in brain centers that are important for sexual behavior; as well as in male reproductive organs, in a pattern suggesting that estrogen may have some role in orgasmic function and genital skin sensitivity. 2. Estrogen restores sexual interest above castrate levels in many vertebrates including reptiles, birds and mammals; but multiple factors contribute to the magnitude of this effect. 3. Data from castrated men, aromatase-deficient men, male-to-female transsexuals, and men on antiandrogens all suggest that estrogen can maintain some libido in androgen-deprived men. We discuss the general benefits of estrogen therapy to quality of life of men on ADT, the potential risks of this treatment, and possible treatment regimes for estrogen therapy in males. Unless contraindicated, we propose that PCa patients on ADT would benefit from supplemental parenteral estrogen.
Keywords: Androgen deprivation therapy; Castrated animals; Estrogen; Libido; Male sexual function; Orgasm; Prostate cancer; Skin sensitivity.
Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.
Similar articles
-
Aucoin MW, Wassersug RJ. Aucoin MW, et al. Soc Sci Med. 2006 Dec;63(12):3162-73. doi: 10.1016/j.socscimed.2006.08.007. Epub 2006 Sep 20. Soc Sci Med. 2006. PMID: 16989928 Review.
-
Parenteral estrogens for prostate cancer: can a new route of administration overcome old toxicities?
Lycette JL, Bland LB, Garzotto M, Beer TM. Lycette JL, et al. Clin Genitourin Cancer. 2006 Dec;5(3):198-205. doi: 10.3816/CGC.2006.n.037. Clin Genitourin Cancer. 2006. PMID: 17239273 Review.
-
Ng E, Woo HH, Turner S, Leong E, Jackson M, Spry N. Ng E, et al. J Urol. 2012 Jun;187(6):2162-6. doi: 10.1016/j.juro.2012.01.080. Epub 2012 Apr 12. J Urol. 2012. PMID: 22503022 Clinical Trial.
Cited by
-
Vaucher L, Funaro MG, Mehta A, Mielnik A, Bolyakov A, Prossnitz ER, Schlegel PN, Paduch DA. Vaucher L, et al. PLoS One. 2014 Apr 15;9(4):e92425. doi: 10.1371/journal.pone.0092425. eCollection 2014. PLoS One. 2014. PMID: 24736568 Free PMC article.
-
Quality of Life and Sexual Health in the Aging of PCa Survivors.
Gacci M, Baldi E, Tamburrino L, Detti B, Livi L, De Nunzio C, Tubaro A, Gravas S, Carini M, Serni S. Gacci M, et al. Int J Endocrinol. 2014;2014:470592. doi: 10.1155/2014/470592. Epub 2014 Mar 17. Int J Endocrinol. 2014. PMID: 24744780 Free PMC article. Review.
-
Handy AB, Jackowich RA, Wibowo E, Johnson TW, Wassersug RJ. Handy AB, et al. Sex Med. 2016 Mar;4(1):e51-9. doi: 10.1016/j.esxm.2015.11.001. Sex Med. 2016. PMID: 26944778 Free PMC article.
-
Cognitive Impacts of Estrogen Treatment in Androgen-Deprived Males: What Needs to be Resolved.
Wibowo E. Wibowo E. Curr Neuropharmacol. 2017;15(7):1043-1055. doi: 10.2174/1570159X15666170313122555. Curr Neuropharmacol. 2017. PMID: 28294068 Free PMC article. Review.
-
Adverse effects of androgen deprivation therapy for prostate cancer: prevention and management.
Sountoulides P, Rountos T. Sountoulides P, et al. ISRN Urol. 2013 Jul 25;2013:240108. doi: 10.1155/2013/240108. eCollection 2013. ISRN Urol. 2013. PMID: 23984103 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical